Pharmaceuticals, Biotechnology and Life Sciences
Actelion Pharmaceuticals will need to provide more data to evaluate the use of Opsumit in the treatment of adults with inoperable chronic thromboembolic pulmonary hypertension.
Idorsia Ltd has made meaningful collaboration with industry leaders in the six and a half months since the demerger from…
Actelion said on Tuesday that, by decision dated October 25, 2017, the Cantonal Court of the Canton of Basel-Landschaft cancelled all…
André C. Muller, CFO of Idorsia, said: “We launched Idorsia on 15 June 2017 with a fully operational research and development engine and CHF 1 billion in cash. For the shortened financial year of 2017, we expect our non-GAAP operating expenses to be between CHF 180-190 million.”
Johnson & Johnson has announced that, with today’s receipt of approval of the proposed acquisition of Actelion from the European Commission (EC), all regulatory approvals required to complete the transaction have been received.
Johnson & Johnson said its $30 billion tender offer for Swiss biotechnology company Actelion was successful, with the price of the offer being 280 per share for Actelion.
Johnson & Johnson said on Wednesday it will buy a Switzerland-based pharmaceutical company Actelion for $30 billion.
For the last year, Sanofi’s chief executive has made clear his quest for deals to help revive the fortunes of France’s biggest drugmaker.
The market is still waiting. Olivier Brandicourt’s failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors.